Biotechnology company Genentech, part of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Wednesday revealed compelling Phase III results from the ALINA study, showcasing Alecensa's (alectinib) ability to reduce the risk of disease recurrence or death by an unprecedented 76% in individuals with completely resected Stage IB to IIIA ALK-positive non-small cell lung cancer (NSCLC). The study data, presented during ESMO 2023, indicate significant improvement in disease-free survival (DFS) and central nervous system-DFS.

The ALINA study involved 257 patients, with Alecensa demonstrating a median DFS not yet reached, compared to 41.3 months for chemotherapy. Adverse events were consistent with previous trials, with 30% experiencing Grade 3 or 4 AEs on Alecensa, and 5.5% discontinuing treatment due to AEs.

These findings are pivotal given the high recurrence rates in early-stage NSCLC, making effective treatments crucial. Genentech plans to submit data to global health authorities, including the FDA and EMA, following the presentation at the ESMO Congress 2023.

The focus on early-stage lung cancers aligns with Genentech's commitment to providing effective treatment options. Lung cancer, constituting 80-85% of all cases, remains a significant area of investment for the biotechnology leader, which currently has six approved medicines for lung cancer treatment and over 10 in development targeting common genetic drivers or boosting the immune system.

Founded over 40 years ago, Genentech is headquartered in South San Francisco, California, and continues to pioneer discoveries, development and commercialisation of medicines for life-threatening conditions.